Under the agreement announced April 1, BioReference will provide on-site rapid PCR COVID-19 testing to all 30 MLB teams, leveraging Mesa Biotech’s Accula System.
Testing begins on April 1, which is opening day, and will continue throughout the season. With this agreement, BioReference is now supporting all five major professional men’s sports leagues in the United States.
“MLB and our other sports league clients have continued to demonstrate exemplary commitment to the health and safety of their players, employees, and stadium staff throughout the pandemic,” said BioReference Laboratories Executive Chairman Dr. Jon Cohen in a prepared statement.
Click here for original post on NJ BIZ website